ABL2 and chronic myelogenous leukemia, BCR-ABL1 positive: Klümper T et al. showed that expression differences of miR-142-5p between treatment-naive chronic myeloid leukemia patients responding and nonresponding to imatinib therapy suggest a link to oncogenic ABL2, SRI, cKIT, and MCL1 signaling pathways that are critical for the development of therapy resistance [30].